Maybe ...but my wife works in Renal and I can tell U that the 2 Co's with drugs in development that her dept is most interested / hopeful for, are OMER and FGEN .
A lot of confidence in the science and investigators involved in both JMO Kiwi
I thought that too a while ago. They reworked their loan agreement where they can draw down the additional amounts without meeting the market cap requirement (though I believe they passed that with the recent surge).
IMO I think they should raise a good 100M or so to push the pipeline forward. I don't think Omidria will be able to sustain the company.
News 
Market Data 
Discover 
